Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 29

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 29
---
627,419 (9,390)(1.5)%1.1 %Manufacturing200,835 192,309 8,526 4.4 %1.5 %Total revenue$1,032,135 $1,026,117 $6,018 0.6 %1.2 %

The following table presents operating income by reportable segment:

Three Months EndedJune 28, 2025June 29, 2024$ change% changeImpact of FX(in thousands, except percentages)RMS$35,786 $29,948 $5,838 19.5 %2.5 %DSA122,781 138,376 (15,595)(11.3)%1.1 %Manufacturing12,061 37,230 (25,169)(67.6)%0.5 %Unallocated corporate(70,494)(53,902)(16,592)30.8 %0.7 %Total operating income$100,134 $151,652 $(51,518)(34.0)%1.3 %Operating income % of revenue9.7 %14.8 %(510) bps

The following presents and discusses our consolidated financial results by each of our reportable segments:

RMS

Three Months EndedJune 28, 2025June 29, 2024$ change% changeImpact of FX(in thousands, except percentages)Revenue$213,271 $206,389 $6,882 3.3 %1.0 %Cost of revenue (excluding amortization of intangible assets)143,135 142,942 193 0.1 %Selling, general and administrative28,369 27,597 772 2.8 %Amortization of intangible assets5,981 5,902 79 1.3 %Operating income$35,786 $29,948 $5,838 19.5 %2.5 %Operating income % of revenue16.8 %14.5 %230 bps

RMS revenue increased $6.9 million primarily driven by an increase in large research model product revenue, notably within China and from Noveprim, an increase in Insourcing Solutions and GEMS service revenue, and the effect of changes in foreign currency exchange rates; partially offset by a decline in Cell